Nevirapine
7 NDCs across 5 manufacturers|7 Generic,0 Brand
Nevirapine is used to treat acquired immunodeficiency syndrome and HIV infections, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jun 21, 1996, and the first generic was approved May 22, 2012. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $2 million on Nevirapine across 11,000 claims for 1,713 beneficiaries.
Nevirapine is available as 7 NDCs from 5 manufacturers (7 generic, 0 brand), with NADAC prices from $0.13 to $1.57 per EA — the most expensive product costs about 12× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
7
7G / 0B
Manufacturers
5
competing in market
Price Spread
$0.13 – $1.57
per EA
7d Activity
avg +1.5% WoW · of 7 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Mylan Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
5 manufacturers producing NEVIRAPINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
NEVIRAPINE ER 400 MG TABLET | $1.5719 per EA | +3.32% |
NEVIRAPINE ER 400 MG TABLET | $1.5719 per EA | +3.32% |
NEVIRAPINE 200 MG TABLET | $0.1556 per EA | — |
NEVIRAPINE 200 MG TABLET | $0.1472 per EA | +0.25% |
NEVIRAPINE 200 MG TABLET | $0.1472 per EA | +0.25% |
NEVIRAPINE 200 MG TABLET | $0.1472 per EA | +0.25% |
NEVIRAPINE 200 MG TABLET | $0.1314 per EA | — |
Frequently Asked Questions
What is Nevirapine used to treat?
Nevirapine is used to treat acquired immunodeficiency syndrome and HIV infections, per the National Library of Medicine's MED-RT classification.
When did Nevirapine become available as a generic?
FDA approved the first generic Nevirapine (ANDA) on May 22, 2012. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Nevirapine?
In 2024, Medicare Part D spent $2 million on Nevirapine across 11,000 claims for 1,713 beneficiaries.
How many Nevirapine products are on the market?
The Nevirapine drug market contains 7 NDCs from 5 manufacturers — 7 generic and 0 brand products.
What is the price range for Nevirapine?
NADAC reference prices for Nevirapine range from $0.1314 to $1.5719 per EA — the most expensive product costs about 12× the cheapest.
Which manufacturers make Nevirapine?
5 manufacturers list Nevirapine in NADAC. Ranked by number of NDCs, the largest are Mylan Pharmaceuticals Inc. (2), Macleods Pharmaceuticals Limited (2), Amneal Pharmaceuticals LLC (1), Camber Pharmaceuticals Inc. (1), Aurobindo Pharma Limited (1).
How has the price of Nevirapine changed recently?
Over the past 7 days, 5 Nevirapine NDCs rose and 0 fell, with a market-wide average change of +1.5%.